TRIPLE RECEPTOR AGONIST / METABOLIC RESEARCH
Retatrutide (LY3437943) is an investigational peptide agonist of the GIP, GLP-1, and glucagon receptors. Human clinical trials have examined its effects on body weight, metabolic measures, and safety, with larger clinical-development programs continuing to evaluate its efficacy and longer-term profile.
PRIMARY RESEARCH AREAS
GIP receptor signaling; GLP-1 receptor signaling; glucagon receptor signaling; obesity and body-weight regulation; glucose metabolism; cardiometabolic physiology; metabolic disease.
EVIDENCE LEVEL
Extensive human clinical development now includes randomized Phase 2 trials and multiple completed Phase 3 trials. Peer-reviewed Phase 2 evidence has been published, while several Phase 3 TRIUMPH program results have been publicly reported in 2026. Retatrutide remains investigational and broader long-term outcomes continue to be studied.
Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist developed to investigate integrated metabolic signaling across three hormone-receptor pathways.
Retatrutide, also known by the development identifier LY3437943, is an investigational triple-receptor agonist targeting the GIP, GLP-1, and glucagon receptors. The compound was designed to combine three metabolically relevant signaling pathways within a single molecule. GIP and GLP-1 signaling participate in nutrient-responsive endocrine regulation, while glucagon-receptor activity contributes to hepatic glucose regulation, substrate metabolism, and energy physiology. Retatrutide has progressed from early mechanistic and Phase 2 investigation into a large Phase 3 clinical-development program. Interpretation should distinguish peer-reviewed clinical publications from topline Phase 3 results released by the study sponsor.
Retatrutide represents a progression from selective GLP-1 receptor agonism and dual GIP/GLP-1 receptor agonism toward experimental triple-receptor pharmacology. Human research has examined obesity, overweight, type 2 diabetes, body-weight regulation, glycemic outcomes, cardiometabolic variables, safety, and tolerability. The Phase 3 TRIUMPH clinical program has substantially expanded the human evidence base beyond the original Phase 2 studies. As of 2026, positive topline findings have been reported from multiple Phase 3 trials, although full peer-reviewed publication should remain distinguished from sponsor-reported topline findings.
Overlapping research areas provide a rationale for studying the constituents together, but they do not establish additive or synergistic effects.
Evidence for GLOW should be read as separate GHK-Cu, BPC-157, and thymosin beta-4 / TB-500 contexts rather than as evidence for a single tested product. The concise evidence matrix below summarizes the cellular, preclinical, and human landscape.
Retatrutide now has a substantially larger human evidence base than was available during its original Phase 2 development. However, it remains investigational. Important unresolved questions include very-long-term safety, durability of outcomes, effects following discontinuation, comparative effectiveness, population-specific responses, cardiovascular outcomes across different populations, and the precise contribution of glucagon-receptor activation to observed metabolic effects. Phase 3 topline announcements should also be distinguished from complete peer-reviewed trial publications because full publications provide additional methodological and safety detail.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402:529–544. PMID: 37385280. DOI: 10.1016/S0140-6736(23)01053-X. Phase 3 findings are identified separately as 2026 sponsor-reported topline results from the TRIUMPH clinical-development program rather than peer-reviewed publications.
References were reviewed against primary-source or PubMed records. Trial findings are described as study-specific results rather than established long-term outcomes.
Evidence involving individual constituents should be interpreted according to the exact compound, formulation, route, population and endpoint studied. Controlled human evidence specifically evaluating the combined 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 formulation has not been established.
CELLULAR / IN-VITRO EVIDENCE
Mechanistic and receptor-level research helps characterize triple-receptor pharmacology and interactions among GIP, GLP-1, and glucagon signaling. Such evidence should remain distinct from clinical outcome evidence.
ANIMAL / PRECLINICAL EVIDENCE
Preclinical research contributed to understanding the metabolic rationale for simultaneous GIP, GLP-1, and glucagon receptor activation. Human clinical outcomes should be evaluated independently from experimental-model findings.
Randomized controlled human evidence now includes Phase 2 and Phase 3 clinical development. Peer-reviewed Phase 2 trials have evaluated obesity and type 2 diabetes, while the Phase 3 TRIUMPH program has expanded investigation across larger and more diverse metabolic populations. Peer-reviewed results should be distinguished from sponsor-reported topline Phase 3 findings.
Established within peer-reviewed research: Retatrutide activates GIP, GLP-1, and glucagon receptors. Randomized Phase 2 trials demonstrated substantial dose-associated body-weight reductions and measurable metabolic effects in defined study populations. Expanded Phase 3 evidence: Multiple Phase 3 TRIUMPH trials have reported positive topline results involving obesity, overweight, type 2 diabetes, and cardiovascular-risk populations. Still under investigation: long-term benefit-risk profile, durability after discontinuation, comparative outcomes, cardiovascular outcomes across populations, uncommon adverse events, and the relative contribution of individual receptor pathways.
Human safety information now spans a considerably larger clinical-development program than the original Phase 2 studies. In the published Phase 2 obesity trial, gastrointestinal adverse events were the most commonly reported adverse events and were generally dose-related. Dose-dependent increases in heart rate were also observed, peaking around 24 weeks and declining thereafter. Safety interpretation should incorporate complete controlled trial datasets as they become publicly available and should distinguish published safety analyses from preliminary topline announcements.
Priority research questions include very-long-term safety, cardiovascular outcomes, durability of body-weight and metabolic changes, outcomes following discontinuation, comparative effectiveness, population-specific responses, body-composition changes, uncommon adverse events, and the biological contribution of glucagon-receptor signaling. Because retatrutide remains investigational, emerging Phase 3 results should be interpreted within their specific study populations, doses, endpoints, estimands, and trial designs.
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, receptor pharmacology, Phase 2 peer-reviewed clinical evidence, Phase 3 development status, and distinction between published findings and sponsor-reported topline results.